Materials And Products Tenders

Open House Discount Agreements 2024-04 - Rivaroxaban

Open House Originals Discount Agreements 2024-07 - Dapagliflozin

Conclusion of Non-Exclusive Discount Agreements in Accordance with Section 130A Paragraph 8 Sgb V for Various Active Ingredients/S/Combinations with the Possibility of Conclusion at any Time as Part of the So-Called Open House Procedure

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Dupilumab (D11ah05) as Part of a So-Called Open House Model.

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Brinzolamide + Brimonidine, Atc S01ec24 for the Period September 1St, 2024 - August 31St, 2026

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Dapagliflozin (A10bk01) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Evolocumab (C10ax13) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Agreements in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Medicines with the Active Ingredient Midazolam (N05cd08) as Part of a So-Called Open House Model.

Conclusion of Non-Exclusive Discount Contracts in Accordance with Sections 130A Paragraph 8/130C Paragraph 1 Sgb V for Drugs with the Active Ingredient Interferon Beta-1A, Intramuscular Injection (L03ab07) as Part of a So-Called O...

Open House Drug Discount Agreements Emtricitabine, Tenofovir Disoproxil and Rilpivirine, Atc J05ar08